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Rivaroxaban to treat thrombotic antiphospholipid syndrome
Thrombosis is one of the clinical hallmarks of 
antiphospholipid syndrome, a heterogeneous auto-
immune disorder associated with the presence of 
antiphospholipid antibodies.1 Thrombosis can occur 
in any vascular bed, but most patients present with 
venous thrombosis or ischaemic stroke.2 Patients with 
antiphospholipid syndrome have a high risk of recurrent 
thrombotic events. The standard treatment for 
secondary prevention of venous thromboembolism is 
vitamin K antagonists. The intensity of anticoagulation 
needed to optimise prevention of secondary events 
has been debated, with arguments against and 
for high-intensity anticoagulation (international 
normalised ratio [INR] 3·0–4·0). Two randomised 
controlled trials showing that standard-intensity 
anticoagulation (target INR 2·0–3·0) is non-inferior to 
high-intensity treatment3,4 lessened the debate, but 
with the arrival of direct oral anticoagulants targeting 
either thrombin or activated coagulation factor X, the 
discussion has restarted. 
The reported safety of direct oral anticoagulants 
combined with an increase in patients’ wellbeing 
due to reduced need for monitoring are important 
arguments in favour of the use of these drugs for 
secondary prevention of venous thromboembolism. 
Case reports of patients with antiphospholipid 
syndrome who have had thrombosis while taking 
direct oral anticoagulants, however, have raised some 
concerns.5,6 Randomised controlled trials are urgently 
needed to resolve these issues.
In The Lancet Haematology, Hannah Cohen and 
colleagues7 provide evidence that similar anti-
coagulation status can be achieved with rivaroxaban or 
warfarin in patients with antiphospholipid syndrome. 
They did a randomised controlled trial involving 
patients who were taking warfarin for previous venous 
thromboembolism, with a target INR of 2·5. After 
6 months of follow-up during which anticoagulation 
status was assessed, only small diﬀ erences in 
anticoagulation were found, leading the authors to 
conclude that rivaroxaban is non-inferior to warfarin. 
The primary endpoint of the study was a laboratory 
comparison of the eﬃ  cacy of warfarin and rivaroxaban. 
These two drugs have notably diﬀ erent eﬀ ects on the 
coagulation system: warfarin essentially decreases the 
concentrations of several coagulation factors, whereas 
rivaroxaban alters coagulation reaction kinetics by 
interfering with the prothrombinase complex. Thus 
the drugs cannot by compared directly for eﬃ  cacy. 
For this reason, Cohen and colleagues compared 
anticoagulation intensity, assessed with calibrated 
automated thrombography, which is a holistic test of 
coagulation that measures thrombin generation rather 
than ﬁ brin formation. Of note, though, the inherent 
diﬀ erences between warfarin and rivaroxaban remain 
apparent in this assay, making it diﬃ  cult to interpret 
the reported ﬁ ndings. The endogenous thrombin 
potential (the parameter most frequently reported in 
the literature for calibrated automated thrombography), 
indicated inferiority of rivaroxaban. By contrast, peak 
thrombin concentrations, which Cohen and colleagues 
argue more accurately reﬂ ects thrombotic risk than 
endogenous thrombin potential, suggested non-
inferiority, supporting their conclusion of non-inferiority 
of rivaroxaban. Probably the most compelling evidence 
for the similar anticoagulant eﬀ ects with rivaroxaban 
and warfarin was that the plasma concentrations of 
in-vivo markers of coagulation, thrombin–antithrombin 
complexes, D-dimers, and prothrombin fragment 
1.2, were slightly raised in only a few patients in both 
treatment groups.
The most pressing question that needs to be answered 
in relation to the use of direct oral anticoagulants 
for prevention of venous secondary thrombosis in 
patients with antiphospholipid syndrome is whether 
rivaroxaban is non-inferior to warfarin and other 
vitamin K antagonists clinically as well as in the 
laboratory. With 54 patients in the rivaroxaban group 
and 56 patients in the warfarin group, the study by 
Cohen and colleagues7 did not have suﬃ  cient power 
to investigate the clinical eﬃ  cacy of rivaroxaban. 
Nevertheless, no thrombotic recurrences or major bleeds 
were reported in the 6-month follow-up period, which 
suggests that this drug could be a safe and eﬀ ective 
alternative for warfarin in a larger number of patients. 
Nevertheless, some caution should be applied because 
antiphospholipid syndrome is a highly heterogeneous 
disorder in terms of clinical presentation and risk 
proﬁ les. Although Cohen and colleagues recruited a 
well deﬁ ned, homogeneous group of patients, those 
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with the high risk triple-positive phenotype (positive 
for lupus anticoagulant and antibodies against 
β2 glycoprotein I and anticardiolipin8) were under-
represented. Moreover, patients who had had recurrent 
venous thromboembolism while taking standard-
intensity warfarin were excluded. Whether treatment 
with rivaroxaban would be equally eﬃ  cacious in these 
subgroups of patients needs to be assessed. 
Although the ﬁ ndings of Cohen and colleagues are 
hopeful,7 the eﬃ  cacy of rivaroxaban treatment for 
secondary prevention of thrombosis in patients with 
antiphospholipid syndrome remains unclear. The 
outcomes of larger clinical trials investigating these 
questions are eagerly awaited.
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